

GI/Endocrine Tumor Board

GI/Endocrine Tumor Board - 8/19/2025
Moore's Cancer Center
August 19, 2025 – 12:00 PM

Learning Objectives

Upon completion of this session, learners should be able to:

- 1 Explain effective treatment planning to patients.
- 2 Apply NCCN practice guidelines.
- 3 Apply knowledge gained from investigator initiated clinical trials.
- 4 Describe basic scientific concepts related to GI endocrine tumors and how they inform clinical practice and treatment decisions.

Target Audience

Specialties – Academic/Research, Gastroenterology/Hepatology, General Surgery, Medical Genetics, Oncology, Radiation Oncology, Radiology

Professions – Physician, Advanced Practice Nurse, Fellow/Resident, Genetic Counselor, Medical Student, Nurse, Physician Assistant

Accreditation

The University of California San Diego School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of California San Diego School of Medicine designates this live activity for a maximum of 1.50 *AMA PRA Category 1 Credit(s)*[™]. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physician Assistants: AAPA accepts certificates of participation for educational activities certified for *AMA PRA Category 1 Credit*[™] from organizations accredited by ACCME or a recognized state medical society.

Nurses: For the purpose of recertification, the American Nurses Credentialing Center accepts *AMA PRA Category 1 Credits*[™] issued by organizations accredited by the ACCME. For relicensure, the California Board of Registered Nursing accepts *AMA PRA Category 1 Credits*[™].

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME requirement of the American Board of Surgery's Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.50 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

Disclosure Statement

All relevant financial relationships and the nature of those relationships are noted below. All relevant financial relationships have been mitigated.

| Name of individual | Individual's role in activity | Nature of Relationship(s) / Name of Ineligible Company(s) |
|------------------------|-------------------------------|---|
| Kathryn Trulock | Activity Coordinator | Nothing to disclose - 04/14/2025 |
| Shalynn Castro | Activity Coordinator | Nothing to disclose - 04/14/2025 |
| Jeremy Chang, MD | Planning Committee Member | |
| Andrew M Lowy, MD | Course Director, Faculty | Advisor-Silexion Advisor-Revolution Medicines (Relationship has ended) Membership on Advisory Committees or Review Panels, Board Membership, etc.-Kinnate Biopharma (Relationship has ended) Advisor-Steba Biotech (Relationship has ended) - 11/18/2024 |
| Adam Burgoyne, MD, PhD | Co-Director | Speakers Bureau-Deciphera (Relationship has ended) Consulting Fee-AstraZeneca (Any division) Consulting Fee-Genentech (Any division) (Relationship has ended) Consulting Fee-Deciphera (Relationship has ended) Consulting Fee-Exelixis, Inc. (Relationship has ended) Consulting Fee-Eisai, Inc. (Relationship has ended) Speakers Bureau-AstraZeneca (Any division) (Relationship has ended) - 09/09/2024 |

Acknowledgment of Commercial Support

This session has received no commercial support.